Welcome to LookChem.com Sign In|Join Free
  • or
Glycine, N-(2-aminoethyl)-N-methyl-, ethyl ester (9CI) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

690953-90-3

Post Buying Request

690953-90-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

690953-90-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 690953-90-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,9,0,9,5 and 3 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 690953-90:
(8*6)+(7*9)+(6*0)+(5*9)+(4*5)+(3*3)+(2*9)+(1*0)=203
203 % 10 = 3
So 690953-90-3 is a valid CAS Registry Number.

690953-90-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Glycine, N-(2-aminoethyl)-N-methyl-, ethyl ester (9CI)

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:690953-90-3 SDS

690953-90-3Relevant academic research and scientific papers

Fused ring compounds as FGFR4 inhibitors

-

Paragraph 0147; 0153-0157, (2021/10/27)

The heart toxicity is low. High selectivity as FGFR4 inhibitor fused ring compounds, pharmaceutical compositions containing said compounds, useful intermediates and for preparing said compounds, and methods of treating cell proliferative diseases such as cancer using the compounds of the present invention.

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4

Fairhurst, Robin A.,Knoepfel, Thomas,Buschmann, Nicole,Leblanc, Catherine,Mah, Robert,Todorov, Milen,Nimsgern, Pierre,Ripoche, Sebastien,Niklaus, Michel,Warin, Nicolas,Luu, Van Huy,Madoerin, Mario,Wirth, Jasmin,Graus-Porta, Diana,Weiss, Andreas,Kiffe, Michael,Wartmann, Markus,Kinyamu-Akunda, Jacqueline,Sterker, Dario,Stamm, Christelle,Adler, Flavia,Buhles, Alexandra,Schadt, Heiko,Couttet, Philippe,Blank, Jutta,Galuba, Inga,Trappe, J?rg,Voshol, Johannes,Ostermann, Nils,Zou, Chao,Berghausen, J?rg,Del Rio Espinola, Alberto,Jahnke, Wolfgang,Furet, Pascal

supporting information, p. 12542 - 12573 (2020/12/17)

FGF19 signaling through the FGFR4/β-klotho receptor complex has been shown to be a key driver of growth and survival in a subset of hepatocellular carcinomas, making selective FGFR4 inhibition an attractive treatment opportunity. A kinome-wide sequence al

COMPOUND FOR SELECTIVELY INHIBITING KINASE AND USE THEREOF

-

Page/Page column 0068-0069, (2019/11/14)

Provided are a compound of formula (I), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, use thereof as a selective inhibitor for FGFR4 kinase and use thereof in manufacturing a medicament or pharmaceutical composition for treating diseases due to FGFR4 or FGF19. The compound disclosed by the invention has selective and significant inhibitory activities against FGFR4, and has wide application prospect in the field of tumor treatment.

Novel pyridine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating FGFR relating diseases containing the same as an active ingredient

-

Paragraph 0187; 0194-0196, (2018/02/08)

The present invention relates to a novel pyridine derivative, a production method thereof, and a pharmaceutical composition for preventing and treating fibroblast growth factor receptor (FGFR)-associated diseases containing the same as an active ingredient according to the present invention, the novel pyridine derivative, an optical isomer thereof, and a pharmaceutically acceptable salt thereof effectively inhibits FGFR, thereby being useful for preventing or treating FGFR-associated diseases, favorably cancer.COPYRIGHT KIPO 2017

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 690953-90-3